Floatz logo

Treg Cells

Lymphoplasmacytic Lymphoma

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Lymphoplasmacytic Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 3BB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Bendamustine
City of Hope Medical Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →